Free Trial
→ The AI Stock to Keep an Eye on Before Election Day (See Why) (From Prosperity Research) (Ad)tc pixel
NASDAQ:IVVD

Invivyd Q3 2026 Earnings Date & Estimates

Invivyd logo
$0.67 -0.05 (-6.64%)
Closing price 04:00 PM Eastern
Extended Trading
$0.68 +0.00 (+0.55%)
As of 04:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Invivyd is scheduled to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. The conference call is scheduled for 8:30 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call
8:30 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Invivyd in Q3 2026

Invivyd is expected to post earnings of -$0.11 per share on revenue of $15.04 million. In the same quarter a year earlier Invivyd reported -$0.06 per share on revenue of $13.13 million. Invivyd last reported on August 13, 2026, posting -$0.14 per share and missing the -$0.1067 consensus estimate. Invivyd has beaten the consensus EPS estimate in 2 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.11
Expected Revenue
$15.04 million
Prior-Year EPS
-$0.06
Prior-Year Revenue
$13.13 million
Expected Revenue Growth
+14.5%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.14 (Missed by -$0.0333)
Last Quarter Revenue
$14.29 million
EPS Beat Rate
2 of last 8 quarters

Prepare for the Q3 2026 Call

Invivyd Q3 2026 Earnings FAQ

Invivyd (NASDAQ:IVVD) is scheduled to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens.

Invivyd's Q3 2026 earnings conference call is scheduled for Thursday, November 5, 2026 at 8:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Invivyd to post earnings of -$0.11 per share for Q3 2026.

The consensus revenue estimate for Invivyd is $15.04 million for Q3 2026.

Invivyd Earnings Headlines

Arcus Biosciences (NYSE:RCUS) versus Invivyd (NASDAQ:IVVD) Head to Head Review
October 12 at 8:14 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31110350
BTIG Sticks to Its Buy Rating for Invivyd (IVVD)
October 5, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/IVVD/pressreleases/4900082/btig-sticks-to-its-buy-rating-for-invivyd-ivvd/
Palantir and Wall Street are in on it…
Palantir just signed a major AI deal with a company most investors have never heard of. Wall Street has poured billions into this firm, which may have found a solution to the growing AI energy crunch. Unlike pricey chipmakers trading at 40 times earnings, this pure-play AI energy name remains cheap and profitable. See the name and ticker behind this fast-moving story before wider attention catches on.tc pixel
October 12 at 1:00 AM  |  Monument Traders Alliance (Ad)
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 5, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/05/3374414/0/en/invivyd-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html
Invivyd, Inc. Announces Positive Topline Results from Liberty Phase 3 Study Demonstrating Vyd2311 Safety and Tolerability Superior to Mrna-Based Covid-19 Vaccine
September 30, 2026  |  marketscreener.comM
Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine
September 30, 2026  |  marketscreener.comM
See More Invivyd Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Invivyd? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Invivyd and other key companies, straight to your email.

About Invivyd

Invivyd (NASDAQ:IVVD) is a clinical-stage biopharmaceutical company focused on developing antibody-based medicines designed to prevent and treat viral diseases. The company’s approach is intended to provide durable protection against rapidly evolving viruses by using engineered monoclonal antibodies that can be updated as pathogens change.

Invivyd’s leading product is pemivibart, marketed in the United States under the brand name PEMGARDA. The product received emergency use authorization from the U.S. Food and Drug Administration for pre-exposure prophylaxis against COVID-19 in certain moderately to severely immunocompromised individuals for whom vaccination is not expected to provide adequate protection. Invivyd is also advancing additional antibody candidates for infectious disease indications.

The company was founded as Adagio Therapeutics and changed its name to Invivyd in 2023. Based in Waltham, Massachusetts, Invivyd conducts research and clinical development activities intended to support the availability of its antibody therapies in the United States and other markets. The company is led by Mark J. Esser, Ph.D., who serves as president and chief executive officer.

View Invivyd Profile
Earnings Tools